Advertisement

Topics

Efficacy and Safety of Morning Versus Evening Intake of Simvast Controlled Release (CR) Tablet in Patients With Hyperlipidemia

2014-08-27 03:19:30 | BioPortfolio

Summary

The purpose of this study is to evaluate the efficacy and safety of morning versus evening intake of Simvastatin Controlled Release tablet 20mg for 8 weeks in patients with hyperlipidemia. This study will investigate equivalence of the low-density lipoprotein (LDL) cholesterol percent change.

Study Design

Allocation: Randomized, Control: Active Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Conditions

Hyperlipidemia

Intervention

Simvastatin CR

Location

8 Sites
Seoul
Korea, Republic of

Status

Completed

Source

Hanmi Pharmaceutical Company Limited

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:19:30-0400

Clinical Trials [326 Associated Clinical Trials listed on BioPortfolio]

Comparison of the Combination of Fenofibrate and Simvastatin Versus Pravastatin

Mixed or combined hyperlipidemia is a common metabolic disorder characterized by both hypercholesterolemia and hypertriglyceridemia. Statins and fibrates have complementary mechanisms and ...

Comparison of the Combination of Fenofibrate and Simvastatin Versus Atorvastatin

Mixed or combined hyperlipidemia is a common metabolic disorder characterized by both hypercholesterolemia and hypertriglyceridemia. Statins and fibrates have complementary mechanisms and ...

Cholesterol and Pharmacogenetic Study

The overall objective of the CAP study was to determine genetic influences on efficacy of simvastatin treatment with regard to LDL cholesterol reduction and changes in other markers of car...

To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia

To evaluate the efficacy and safety of ezetimibe/simvastatin and niacin in patients with high cholesterol.

Ezetimibe Plus Simvastatin Versus Simvastatin in Untreated Subjects With High Cholesterol (P03435)(COMPLETED)

This study will assess whether co-administration of ezetimibe 10 mg with simvastatin 20 mg will be more effective than treatment with simvastatin 20 mg alone in reducing LDL-C concentratio...

PubMed Articles [181 Associated PubMed Articles listed on BioPortfolio]

Simvastatin accelerates hematoma resolution after intracerebral hemorrhage in a PPARγ-dependent manner.

To date, the neuroprotective effects of statins on intracerebral hemorrhage (ICH) are not well established. This study explored the effect and potential mechanism of simvastatin treatment on ICH. In t...

Effect of antiretroviral therapy use and adherence on the risk of hyperlipidemia among HIV-infected patients, in the highly active antiretroviral therapy era.

HIV-infected patients exposed to antiretroviral therapy (ART) have an increased risk for hyperlipidemia and cardiovascular disease. We performed a longitudinal, comprehensive, and population-based stu...

Simvastatin alters M1/M2 polarization of murine BV2 microglia via Notch signaling.

Microglia play a critical role in the regulation of CNS immune function, which can be greatly affected by M1/M2 polarization. The role of Notch signaling in Statins induced alteration of M1/M2 polariz...

Central xanthoma of the mandible associated with hyperlipidemia: A rare presentation.

Xanthoma is a common, self-limiting cutaneous lesion of non-Langerhans cell, lipid-laden foamy histiocytes that is often concomitant with hyperlipidemia. The intraosseous counterpart is rarely encount...

Association of Antituberculosis Treatment and Lower Risk of Hyperlipidemia in Taiwanese Patients: A Population-Based Case-Control Study.

The association between anti-tuberculosis (TB) treatments and the risk of developing hyperlipidemia remains unclear. Data were obtained from the Longitudinal Health Insurance Database 2000 (LHID2000)....

Medical and Biotech [MESH] Definitions

A pharmaceutical preparation of ezetimibe and simvastatin that is used in the treatment of HYPERCHOLESTEROLEMIA and HYPERLIPIDEMIAS.

A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL.

Common occlusive arterial disease which is caused by ATHEROSCLEROSIS. It is characterized by lesions in the innermost layer (ARTERIAL INTIMA) of arteries including the AORTA and its branches to the extremities. Risk factors include smoking, HYPERLIPIDEMIA, and HYPERTENSION.

A type of familial lipid metabolism disorder characterized by a variable pattern of elevated plasma CHOLESTEROL and/or TRIGLYCERIDES. Multiple genes on different chromosomes may be involved, such as the major late transcription factor (UPSTREAM STIMULATORY FACTORS) on CHROMOSOME 1.

Rare and often fatal drug complication which affects patients undergoing long-term treatment with high doses of PROPOFOL. It is characterized by METABOLIC ACIDOSIS; HYPERLIPIDEMIA; RHABDOMYOLYSIS; cardiovascular CIRCULATORY COLLAPSE; CARDIAC FAILURE; and KIDNEY FAILURE.

More From BioPortfolio on "Efficacy and Safety of Morning Versus Evening Intake of Simvast Controlled Release (CR) Tablet in Patients With Hyperlipidemia"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Statins
Statins (or HMG-CoA reductase inhibitors) are a class of drug used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase, which plays a central role in the production of cholesterol in the liver. Increased cholesterol levels have been as...


Searches Linking to this Trial